ReviewBiological psychiatry2013
Human biomarkers of rapid antidepressant effects.
Review in Biological psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04480918 (University of Iowa Interventional Psychiatry Service Patient Registry), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
University of Iowa Interventional Psychiatry Service Patient Registry
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.Molecular psychiatry · 2022Pooled it
- Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.Journal of child and adolescent psychopharmacology · 2024Trial
- Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis.Neuropsychiatric disease and treatment · 2023Trial
- Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.The international journal of neuropsychopharmacology · 2019Trial
- Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
- Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.Journal of psychiatric research · 2014Trial
- Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.The international journal of neuropsychopharmacology · 2014Trial
- Clinical predictors of ketamine response in treatment-resistant major depression.The Journal of clinical psychiatry · 2014Trial
- The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression.Molecular psychiatry · 2026Article
- Trace Elements Levels in Major Depressive Disorder-Evaluation of Potential Threats and Possible Therapeutic Approaches.International journal of molecular sciences · 2023Review
- Early post-treatment blood oxygenation level-dependent responses to emotion processing associated with clinical response to pharmacological treatment in major depressive disorder.Brain and behavior · 2021Article
- Astrocyte Intracellular CaNeurotoxicity research · 2021Article
- Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence.Nutrients · 2021Review
- Nitrous oxide as a putative novel dual-mechanism treatment for bipolar depression: Proof-of-concept study design and methodology.Contemporary clinical trials communications · 2020Article
- Device-Based Modulation of Neurocircuits as a Therapeutic for Psychiatric Disorders.Annual review of pharmacology and toxicology · 2020Review
- Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.Translational psychiatry · 2018Article
- Sex Differences in the Pharmacokinetics of Low-dose Ketamine in Plasma and Brain of Male and Female Rats.The Journal of pharmacology and experimental therapeutics · 2018Article
- Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales.Journal of affective disorders · 2018Article
- Convergent Mechanisms Underlying Rapid Antidepressant Action.CNS drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mood disorders such as major depressive disorder and bipolar disorder--and their consequent effects on the individual and society--are among the most disabling and costly of all medical illnesses. Although a number of antidepressant treatments are available in clinical practice, many patients still undergo multiple and lengthy medication trials before experiencing relief of symptoms. Therefore a tremendous need exists to improve current treatment options and to facilitate more rapid, successful treatment in patients suffering from the deleterious neurobiological effects of ongoing depression. Toward that end, ongoing research is exploring the identification of biomarkers that might be involved in prevention, diagnosis, treatment response, severity, or prognosis of depression. Biomarkers evaluating treatment response will be the focus of this review, given the importance of providing relief to patients in a more expedient and systematic manner. A novel approach to developing such biomarkers of response would incorporate interventions with a rapid onset of action--such as sleep deprivation or intravenous drugs (e.g., ketamine or scopolamine). This alternative translational model for new treatments in psychiatry would facilitate shorter studies, improve feasibility, and increase higher compound throughput testing for these devastating disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.